McGeorge Anne: insider trades.
McGeorge Anne reported 8 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($845K), across 2 companies.
- Transactions
- 8
- Purchases (P)
- 0
- Sales (S)
- 5
- Companies
- 2
- Name as filed
- McGeorge Anne
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | Director | 7 |
| Oncology Institute, Inc. (STLN) | Director | 1 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | S | 1,000 | $110.64 | 700 | Form 4 |
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | S | 700 | $111.41 | 0 | Form 4 |
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | S | 1,800 | $109.3 | 1,700 | Form 4 |
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | S | 2,800 | $108.38 | 3,500 | Form 4 |
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | S | 1,450 | $107.58 | 6,300 | Form 4 |
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | M | 6,500 | $11.2 | 7,750 | Form 4 |
| 2026-08-10 | Dianthus Therapeutics, Inc. /DE/ | M | 1,250 | $19.36 | 1,250 | Form 4 |
| 2026-07-27 | Oncology Institute, Inc. | A | 41,165 | $0 | 332,535 | Form 4 |
Questions
What stock did McGeorge Anne buy or sell?
McGeorge Anne reported 8 non-derivative transactions on 2 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($845K), across 2 companies.
Is McGeorge Anne the same person as other filers with this name?
This page covers SEC CIK 1779934 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/mcgeorge-anne-1779934.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.